<div id="readability-page-1"><p>Evolent Health (NYSE:EVH - Get Free Report) is expected to post its  Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect Evolent Health to post earnings of $0.06 per share and revenue of $468.4810 million for the quarter. Individuals may visit the the company's upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 5:00 PM ET.</p><div><p><span></span><span>Get <strong>Evolent Health</strong> alerts:</span></p></div><h2>Evolent Health Price Performance</h2><p>Shares of NYSE EVH opened at $2.79 on Tuesday. The company has a debt-to-equity ratio of 1.25, a quick ratio of 1.33 and a current ratio of 1.33. Evolent Health has a one year low of $2.56 and a one year high of $12.06. The company's fifty day moving average is $3.69 and its two-hundred day moving average is $6.16. The firm has a market capitalization of $310.81 million, a P/E ratio of -1.76 and a beta of 0.27. </p><h2>Institutional Investors Weigh In On Evolent Health</h2><p>Institutional investors and hedge funds have recently modified their holdings of the stock. Brighton Jones LLC acquired a new position in shares of  Evolent Health in the 4th quarter valued at about $3,927,000.  MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in  Evolent Health by 2.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 128,527 shares of the technology company's stock worth $1,217,000 after buying an additional 3,572 shares in the last quarter.  Goldman Sachs Group Inc. boosted its stake in shares of  Evolent Health by 162.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,836,402 shares of the technology company's stock valued at $26,861,000 after buying an additional 1,754,520 shares during the period.  Caxton Associates LLP acquired a new stake in shares of  Evolent Health during the 1st quarter valued at $252,000.  Finally, Strs Ohio purchased a new position in shares of  Evolent Health during the 1st quarter valued at $47,000. </p><h2>Analyst Ratings Changes</h2><p>Several analysts have recently weighed in on EVH shares. Truist Financial lowered their target price on Evolent Health from $16.00 to $10.00 and set a &#34;buy&#34; rating for the company in a research note on Monday, November 10th. Citigroup dropped their price objective on Evolent Health from $9.50 to $6.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, January 9th. Piper Sandler  set a $6.00 price target on shares of Evolent Health in a research report on Tuesday, December 2nd. BTIG Research dropped their price target on shares of Evolent Health from $16.00 to $10.00 and set a &#34;buy&#34; rating for the company in a research note on Monday, February 2nd. Finally, Weiss Ratings  reaffirmed a &#34;sell (e+)&#34; rating on shares of Evolent Health in a report on Monday, December 29th. Thirteen research analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has assigned  a Sell rating to the stock. According to data from MarketBeat.com, the company  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $9.77.</p><p><b>Get Our Latest Report on EVH</b></p><h2>Evolent Health Company Profile</h2> (Get Free Report)<p>Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.  </p><p>The company's core offerings include care management solutions, population health analytics and clinical advisory services.</p><h2>Read More</h2><ul><li>Five stocks we like better than Evolent Health</li><li>Your Bank Account Is No Longer Safe</li><li>Nvidia CEO Issues Bold Tesla Call</li><li>Buy this Gold Stock Before May 2026</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>This $15 Stock Could Go Down as the #1 Stock of 2026</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVWSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVWSA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Evolent Health Right Now?</h2><p>Before you consider Evolent Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolent Health wasn't on the list.</p><p>While Evolent Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Evolent Health (NYSE:EVH) is set to announce its Q4 2025 earnings on February 24, with expectations of $0.06 per share and $468.48 million in revenue. The company's shares opened at $2.79, with a market cap of $310.81 million. Analysts have mixed ratings, with a consensus rating of "Moderate Buy" and a price target of $9.77. Recent institutional investments include Brighton Jones LLC and Goldman Sachs Group Inc. Evolent Health focuses on healthcare technology and services, aiding clients in transitioning to value-based care.</p>

Evolent Health (EVH) Expected to Announce Quarterly Earnings on Tuesday